PhRMA comments to administration on International Pricing Index Model

______________________________________________________________________________________________

As 2018 came to a close, PhRMA submitted comments on the administration’s proposed International Pricing Index (IPI) Model for Medicare Part B medicines. The comments highlighted concerns and encouraged the administration to abandon the model altogether. In case you missed it, here are a few key excerpts: